Title:
NOVEL FGFR3 FUSION PRODUCT
Document Type and Number:
WIPO Patent Application WO/2013/133351
Kind Code:
A1
Abstract:
The purpose of the present invention is to elucidate a polynucleotide which is a new cancer-causing gene, and to thereby provide: a method for detecting the polynucleotide or a polypeptide encoded by the polynucleotide; a kit for detection; a probe set; and a primer set. Another purpose is to provide a pharmaceutical composition for treating cancer. This detection method detects a fusion gene that comprises a part of the FGFR3 gene and a part of the TACC3 gene, or a fusion protein encoded by the fusion gene. Said primer set, probe set, and kit for detection each contains a sense primer and a probe set which are designed from the part that encodes FGFR3 and an antisense primer and a probe set which are designed from the part that encodes TACC3. A cancer-treating pharmaceutical composition that is positive to said fusion gene or positive to said polypeptide is provided, because an inhibitor of said polypeptide exhibits an antitumor effect.
Inventors:
SUZUKI ATSUSHI (JP)
ASAUMI MAKOTO (JP)
TSUNOYAMA KAZUHISA (JP)
NISHIMURA KOUICHI (JP)
MORINAKA AKIFUMI (JP)
YAMAUCHI TOMOHIRO (JP)
YOSHINO MASAYASU (JP)
YOSHIZAKI HIROAKI (JP)
ASAUMI MAKOTO (JP)
TSUNOYAMA KAZUHISA (JP)
NISHIMURA KOUICHI (JP)
MORINAKA AKIFUMI (JP)
YAMAUCHI TOMOHIRO (JP)
YOSHINO MASAYASU (JP)
YOSHIZAKI HIROAKI (JP)
Application Number:
PCT/JP2013/056225
Publication Date:
September 12, 2013
Filing Date:
March 07, 2013
Export Citation:
Assignee:
ASTELLAS PHARMA INC (JP)
International Classes:
C12N15/09; A61K45/00; A61P35/00; C12Q1/68; G01N33/53
Domestic Patent References:
| WO2008075068A2 | 2008-06-26 | |||
| WO2010129509A1 | 2010-11-11 |
Other References:
WILLIAMS SV. ET AL.: "Oncogenic FGFR3 gene fusions in bladder cancer.", HUM. MOL. GENET., vol. 22, no. 4, 15 February 2013 (2013-02-15), pages 795 - 803, XP055105338
SINGH D. ET AL.: "Transforming fusions of FGFR and TACC genes in human glioblastoma", SCIENCE, vol. 337, no. 6099, 7 September 2012 (2012-09-07), pages 1231 - 1235, XP055127902
ZHAO G. ET AL.: "A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models", MOL. CANCER THER., vol. 10, no. 11, 2011, pages 2200 - 2210, XP055160880
PARKER BC. ET AL.: "The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma", J. CLIN. INVEST., vol. 123, no. 2, 1 February 2013 (2013-02-01), pages 855 - 865, XP055127845
SODERBERG 0. ET AL.: "Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay", METHODS, vol. 45, no. 3, 2008, pages 227 - 232, XP023437838
JARVIUS M. ET AL.: "In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method", MOL. CELL. PROTEOMICS, vol. 6, no. 9, 2007, pages 1500 - 1509, XP002635677
NILSSON I. ET AL.: "VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts", EMBO J., vol. 29, no. 8, 2010, pages 1377 - 1388, XP055160883
GREULICH H. ET AL.: "Targeting mutant fibroblast growth factor receptors in cancer", TRENDS MOL. MED., vol. 17, no. 5, 2011, pages 283 - 292, XP028206232
SOMAIAH N. ET AL.: "Molecular targeted agents and biologic therapies for lung cancer", J. THORAC. ONCOL., vol. 6, 2011, pages 1758 - 1785, XP055160896
AVET-LOISEAU H. ET AL.: "High incidence of translocations t(11;14)(q13;q32) and t(4;14) (p16;q32) in patients with plasma cell malignancies", CANCER RES., vol. 58, no. 24, 1998, pages 5640 - 5645, XP055160897
YAGASAKI F. ET AL.: "Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12) (p16;p13) chromosomal translocation", CANCER RES., vol. 61, no. 23, 2001, pages 8371 - 8374, XP055160898
CYTOKINE & GROWTH FACTOR REVIEW, vol. 16, 2005, pages 139 - 149
BIOCHEMICAL JOURNAL, vol. 437, 2011, pages 199 - 213
BLOOD, vol. 100, 2002, pages 1579 - 1583
CANCER RESEARCH, vol. 61, 2001, pages 8371 - 8374
ONCOGENE, vol. 28, 2009, pages 4306 - 4316
TRENDS IN CELL BIOLOGY, vol. 18, 2008, pages 379 - 388
SCIENCE, vol. 337, no. 6099, 26 July 2012 (2012-07-26), pages 1231 - 5
HUM MOL GENET., 21 November 2012 (2012-11-21)
HUM MOL GENET., vol. 22, no. 4, 15 February 2013 (2013-02-15), pages 795 - 803
J CLIN INVEST., vol. 123, no. 2, 1 February 2013 (2013-02-01), pages 855 - 865
CLIN. CANCER RES., vol. 7L, no. 1, 2009, pages 9 - 7123
CLIN. CANCER RES., 2009, pages 3143 - 3149
NAT MED., vol. 18, no. 3, 12 February 2012 (2012-02-12), pages 375 - 7
NATURE, 2007, pages 561 - 566
NATURE MEDICINE, 12 February 2012 (2012-02-12)
CLIN. CANCER RES., 2008, pages 4275 - 4283
DRUG DES. DEVEL. THER., 2011, pages 471 - 485
J MOL BIOL, vol. 48, 1970, pages 443 - 453
J. MOL. DIAGN., 2012, pages 22 - 29
GENOME RES., vol. 6, no. 10, 1996, pages 986
NAT. METHODS., 2006, pages 995 - 1000
CLINICAL CANCER RESEARCH, vol. 17, 2011, pages 7451 - 7461
JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, 2011, pages 7066 - 7083
MOL CANCER THER, vol. 1 0, 2011, pages 2200 - 2210
"Clinical Oncology", JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY
N. TERRETT ET AL., DRUG DISCOV. TODAY, vol. 4, no. 1, 1999, pages 41
SINGH D. ET AL.: "Transforming fusions of FGFR and TACC genes in human glioblastoma", SCIENCE, vol. 337, no. 6099, 7 September 2012 (2012-09-07), pages 1231 - 1235, XP055127902
ZHAO G. ET AL.: "A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models", MOL. CANCER THER., vol. 10, no. 11, 2011, pages 2200 - 2210, XP055160880
PARKER BC. ET AL.: "The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma", J. CLIN. INVEST., vol. 123, no. 2, 1 February 2013 (2013-02-01), pages 855 - 865, XP055127845
SODERBERG 0. ET AL.: "Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay", METHODS, vol. 45, no. 3, 2008, pages 227 - 232, XP023437838
JARVIUS M. ET AL.: "In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method", MOL. CELL. PROTEOMICS, vol. 6, no. 9, 2007, pages 1500 - 1509, XP002635677
NILSSON I. ET AL.: "VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts", EMBO J., vol. 29, no. 8, 2010, pages 1377 - 1388, XP055160883
GREULICH H. ET AL.: "Targeting mutant fibroblast growth factor receptors in cancer", TRENDS MOL. MED., vol. 17, no. 5, 2011, pages 283 - 292, XP028206232
SOMAIAH N. ET AL.: "Molecular targeted agents and biologic therapies for lung cancer", J. THORAC. ONCOL., vol. 6, 2011, pages 1758 - 1785, XP055160896
AVET-LOISEAU H. ET AL.: "High incidence of translocations t(11;14)(q13;q32) and t(4;14) (p16;q32) in patients with plasma cell malignancies", CANCER RES., vol. 58, no. 24, 1998, pages 5640 - 5645, XP055160897
YAGASAKI F. ET AL.: "Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12) (p16;p13) chromosomal translocation", CANCER RES., vol. 61, no. 23, 2001, pages 8371 - 8374, XP055160898
CYTOKINE & GROWTH FACTOR REVIEW, vol. 16, 2005, pages 139 - 149
BIOCHEMICAL JOURNAL, vol. 437, 2011, pages 199 - 213
BLOOD, vol. 100, 2002, pages 1579 - 1583
CANCER RESEARCH, vol. 61, 2001, pages 8371 - 8374
ONCOGENE, vol. 28, 2009, pages 4306 - 4316
TRENDS IN CELL BIOLOGY, vol. 18, 2008, pages 379 - 388
SCIENCE, vol. 337, no. 6099, 26 July 2012 (2012-07-26), pages 1231 - 5
HUM MOL GENET., 21 November 2012 (2012-11-21)
HUM MOL GENET., vol. 22, no. 4, 15 February 2013 (2013-02-15), pages 795 - 803
J CLIN INVEST., vol. 123, no. 2, 1 February 2013 (2013-02-01), pages 855 - 865
CLIN. CANCER RES., vol. 7L, no. 1, 2009, pages 9 - 7123
CLIN. CANCER RES., 2009, pages 3143 - 3149
NAT MED., vol. 18, no. 3, 12 February 2012 (2012-02-12), pages 375 - 7
NATURE, 2007, pages 561 - 566
NATURE MEDICINE, 12 February 2012 (2012-02-12)
CLIN. CANCER RES., 2008, pages 4275 - 4283
DRUG DES. DEVEL. THER., 2011, pages 471 - 485
J MOL BIOL, vol. 48, 1970, pages 443 - 453
J. MOL. DIAGN., 2012, pages 22 - 29
GENOME RES., vol. 6, no. 10, 1996, pages 986
NAT. METHODS., 2006, pages 995 - 1000
CLINICAL CANCER RESEARCH, vol. 17, 2011, pages 7451 - 7461
JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, 2011, pages 7066 - 7083
MOL CANCER THER, vol. 1 0, 2011, pages 2200 - 2210
"Clinical Oncology", JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY
N. TERRETT ET AL., DRUG DISCOV. TODAY, vol. 4, no. 1, 1999, pages 41
Attorney, Agent or Firm:
MORITA, Hiroshi et al. (JP)
Morita 拓 (JP)
Morita 拓 (JP)
Download PDF:
Claims: